肾移植后复发性C3肾小球病的临床管理
该综述聚焦肾移植后复发性C3肾小球病(C3G)的管理。文章指出C3G移植后常早期复发且多为亚临床型,目前缺乏可靠预测复发的生物标志物,预防策略未获验证,因此主张采用以监测驱动的务实管理框架,而非预防性干预。
要点
- C3G移植后复发常见且可呈亚临床型,方案活检有助于早期发现。
- 目前无可靠临床、遗传或功能生物标志物预测复发,预防策略未获验证。
- 管理应以监测驱动为核心,兼顾移植候选评估、移植后监测与治疗决策。
核心结论
- 复发性C3G管理应采取务实的监测驱动策略,而非预防性干预。
研究设计与样本
- 综述,从移植中心临床视角总结移植候选评估、移植后监测及治疗决策框架。
主要发现
- C3G移植后常早期复发,且常表现为亚临床型。
- 目前无 validated 的临床、遗传或功能生物标志物可可靠预测复发。
- 预防性策略仍未被证实有效。
临床怎么用
- 将方案活检纳入移植后监测以发现亚临床复发。
- 在缺乏可靠预测标志物的情况下,避免预防性干预,采用监测驱动决策。
- 关注近端补体抑制剂在复发性C3G中的新兴地位。
局限性
- 治疗目标仍不明确。
- 亚临床组织学复发的管理尚不确定。
- 治疗反应的解读存在困难。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
C3 glomerulopathy (C3G) is an ultra-rare, complement-mediated glomerular disease characterized by dysregulation of the alternative complement pathway and a high propensity for recurrence after kidney transplantation. Although kidney transplantation remains the optimal treatment for patients reaching kidney failure, post-transplant recurrence continues to be a major cause of graft dysfunction and loss. Over the past decade, improved histopathologic recognition and the increasing adoption of protocol biopsies have revealed that C3G frequently recurs early after transplantation, often in a subclinical form. At present, no validated clinical, genetic, or functional biomarkers reliably predict recurrence, and preventive strategies remain unproven. Consequently, from our standpoint, management of recurrent C3G requires a pragmatic, surveillance-driven approach rather than prophylactic intervention. In this review, we provide a practical framework for managing recurrent C3G after kidney transplantation, from transplant candidacy and pre-transplant evaluation to post-transplant monitoring and therapeutic decision-making. We discuss the role of protocol biopsies, the limitations of conventional immunosuppression, and the emerging place of proximal complement inhibitors. Finally, we highlight several unmet needs that continue to limit optimal care, including persistent uncertainty about therapeutic goals, management of subclinical histologic recurrence, and interpretation of treatment response. This review reflects a transplant-centered clinical perspective aimed at supporting nephrologists in real-world decision-making.
引用
- Trujillo H, Cavero T, Moran SM, et al. Management of Recurrent C3 Glomerulopathy After Kidney Transplantation. Nephrol Dial Transplant. 2026. PMID: 42578942. doi:10.1093/ndt/gfag183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。